Last reviewed · How we verify
Zavegepant 10 mg IN (zavegepant-10-mg-in)
Zavegepant 10 mg IN (generic name: zavegepant-10-mg-in) is a drug developed by Pfizer Inc.. It is currently in Phase 1 development.
Zavegepant is a small molecule that acts as a calcitonin gene-related peptide type 1 receptor antagonist. It is being studied as a treatment for multiple migraine attacks in adult participants, with a specific dose of 10 mg being investigated in clinical trials.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Big-pharma sponsor
+3.0pp
Pfizer Inc. is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | zavegepant-10-mg-in |
|---|---|
| Sponsor | Pfizer Inc. |
| Phase | Phase 1 |
Approved indications
Common side effects
- Dysgeusia
- Nasal discomfort
- Headache
- Scar
- Skin laceration
- Nausea
- Dizziness
- Nasal congestion
- Oral discomfort
- Asthenia
- Fatigue
- Fall
Key clinical trials
- A Study to Compare Zavegepant Concentration Using Samples Collected From the Vein Versus Patient-Centric Microsampling (PHASE1)
- A Study to Learn About Zavegepant as a Treatment for Multiple Migraine Attacks in Adult Participants (PHASE3)
- Acute Migraine Treatment in the ED With Gepants (PHASE4)
- A Study to Learn About the Study Medicine Called Zavegepant in Healthy Chinese Adult Participants (PHASE1)
- Acute Treatment Trial in Adult Subjects With Migraines (PHASE2, PHASE3)
- Randomized Trial in Adult Participants With Acute Migraines (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Zavegepant 10 mg IN CI brief — competitive landscape report
- Zavegepant 10 mg IN updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI
Frequently asked questions about Zavegepant 10 mg IN
What is Zavegepant 10 mg IN?
Who makes Zavegepant 10 mg IN?
What is the generic name of Zavegepant 10 mg IN?
What development phase is Zavegepant 10 mg IN in?
What are the side effects of Zavegepant 10 mg IN?
Related
- Manufacturer: Pfizer Inc. — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing